Orion Oyj
XMUN:OFK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Orion Oyj
XMUN:OFK
|
FI |
|
Norsk Hydro ASA
OTC:NHYKF
|
NO |
|
CG Power and Industrial Solutions Ltd
NSE:CGPOWER
|
IN |
|
NWS Holdings Ltd
HKEX:659
|
HK |
|
Grupo Bimbo SAB de CV
F:4GM
|
MX |
|
Centamin PLC
LSE:CEY
|
JE |
|
EDM Resources Inc
OTC:EDMFF
|
CA |
|
Pros Holdings Inc
NYSE:PRO
|
US |
|
Stora Enso Oyj
OTC:SEOAY
|
FI |
|
Relief Therapeutics Holding SA
OTC:RLFTF
|
CH |
|
MS International PLC
OTC:MSILF
|
UK |
|
InPlay Oil Corp
TSX:IPO
|
CA |
|
Granite Real Estate Investment Trust
TSX:GRT.UN
|
CA |
|
Poxel SA
PAR:POXEL
|
FR |
|
H
|
Helix Energy Solutions Group Inc
XMUN:CTV
|
US |
|
S
|
Stora Enso Oyj
STO:STE A
|
FI |
|
Banco Comercial Portugues SA
ELI:BCP
|
PT |
|
Hexatronic Group AB
OTC:HTROF
|
SE |
|
Bank Tabungan Negara (Persero) Tbk PT
F:TA2
|
ID |
|
M
|
MKS Instruments Inc
F:MKT
|
US |
|
D
|
Daily Mail and General Trust P L C
F:DGW2
|
UK |
|
B
|
Bri-Chem Corp
TSX:BRY
|
CA |
|
Amcor PLC
OTC:AMCCF
|
UK |
|
Brixmor Property Group Inc
NYSE:BRX
|
US |
Orion Oyj
Orion Oyj is a Finnish pharmaceutical company that develops, manufactures, and sells medicines for people and animals. Its main products include prescription drugs, over-the-counter medicines, and veterinary medicines, with a strong focus on treatments for the central nervous system, cancer care, and animal health. The company also makes active pharmaceutical ingredients and other drug-related products that it sells to partners in the healthcare industry. Orion sells its products to pharmacies, hospitals, doctors, veterinarians, and other drug companies. It earns money mainly by selling branded medicines, generic medicines, and pharmaceutical ingredients, plus royalties and license income from drug development partnerships. In practice, Orion sits between research and the end market: it turns drug research and manufacturing know-how into finished medicines that can be sold under its own brands or by partners. What makes Orion different is its mix of human health, animal health, and drug ingredient businesses under one roof. That gives it multiple ways to make money from the same scientific and manufacturing base, while reducing reliance on any single product line. For beginner investors, the key point is that Orion is not a broad healthcare company; it is a focused drug maker that competes through pharmaceutical research, regulatory expertise, and reliable production.
Orion Oyj is a Finnish pharmaceutical company that develops, manufactures, and sells medicines for people and animals. Its main products include prescription drugs, over-the-counter medicines, and veterinary medicines, with a strong focus on treatments for the central nervous system, cancer care, and animal health. The company also makes active pharmaceutical ingredients and other drug-related products that it sells to partners in the healthcare industry.
Orion sells its products to pharmacies, hospitals, doctors, veterinarians, and other drug companies. It earns money mainly by selling branded medicines, generic medicines, and pharmaceutical ingredients, plus royalties and license income from drug development partnerships. In practice, Orion sits between research and the end market: it turns drug research and manufacturing know-how into finished medicines that can be sold under its own brands or by partners.
What makes Orion different is its mix of human health, animal health, and drug ingredient businesses under one roof. That gives it multiple ways to make money from the same scientific and manufacturing base, while reducing reliance on any single product line. For beginner investors, the key point is that Orion is not a broad healthcare company; it is a focused drug maker that competes through pharmaceutical research, regulatory expertise, and reliable production.
Strong quarter: Orion said Q2 net sales rose 25% to EUR 522 million and operating profit rose 69%, with growth led by Nubeqa royalties and innovative medicines.
Guidance raised: Management lifted the low end of full-year net sales guidance by EUR 50 million, to EUR 2 billion-EUR 2.1 billion, and set EBIT guidance at EUR 650 million-EUR 750 million.
Nubeqa momentum: Royalty income was the main profit driver, and management said the highest royalty tier was reached in Q2, which should support results for the rest of the year.
R&D progress: Orion highlighted ODM-212 as a key pipeline asset, with Phase II ongoing and no plan to seek a partner at this stage.
Other businesses: Branded Products, Generics, and Fermion all contributed, while Animal Health was softer in Q2; management said the Hanko water damage should not have a material impact.
